BioVie IncNASDAQ:BIVINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4748
- TODAY'S CHANGE (%)0.0438 (10.1624%)
- Bid / Lots0.4737/ 6
- Ask / Lots0.4759/ 3
- Open / Previous Close0.4390 / 0.4310
- Day Range
- 52 Week Range
- Volume764,300
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIVI |
|---|---|---|
| 09:32 ET | 5129 | 0.44 |
| 09:34 ET | 876 | 0.4365 |
| 09:38 ET | 200 | 0.4373 |
| 09:43 ET | 29770 | 0.4271 |
| 09:45 ET | 4060 | 0.4212 |
| 09:48 ET | 1601 | 0.4208 |
| 09:50 ET | 600 | 0.421 |
| 09:52 ET | 25531 | 0.4202 |
| 09:54 ET | 400 | 0.421 |
| 09:56 ET | 390 | 0.421103 |
| 09:57 ET | 340 | 0.4221 |
| 09:59 ET | 6853 | 0.4215 |
| 10:01 ET | 100 | 0.4224 |
| 10:03 ET | 800 | 0.4235 |
| 10:06 ET | 359 | 0.4229 |
| 10:08 ET | 1200 | 0.4219 |
| 10:14 ET | 12691 | 0.4228 |
| 10:15 ET | 200 | 0.4221 |
| 10:17 ET | 1292 | 0.4214 |
| 10:19 ET | 2200 | 0.4224 |
| 10:21 ET | 2000 | 0.4215 |
| 10:24 ET | 10951 | 0.4221 |
| 10:26 ET | 3300 | 0.4216 |
| 10:28 ET | 3104 | 0.4226 |
| 10:30 ET | 10530 | 0.425 |
| 10:32 ET | 2270 | 0.4249 |
| 10:33 ET | 1500 | 0.4249 |
| 10:37 ET | 1100 | 0.4274 |
| 10:39 ET | 100 | 0.4268 |
| 10:42 ET | 100 | 0.4318 |
| 10:46 ET | 200 | 0.4346 |
| 10:48 ET | 520 | 0.4321 |
| 10:50 ET | 200 | 0.4352 |
| 10:51 ET | 850 | 0.4332 |
| 10:53 ET | 100 | 0.43375 |
| 10:55 ET | 200 | 0.4337 |
| 10:57 ET | 7350 | 0.4337 |
| 11:00 ET | 400 | 0.433701 |
| 11:02 ET | 100 | 0.4337 |
| 11:06 ET | 200 | 0.4337 |
| 11:11 ET | 100 | 0.4386 |
| 11:13 ET | 2429 | 0.4321 |
| 11:15 ET | 100 | 0.4322 |
| 11:18 ET | 4160 | 0.4273 |
| 11:20 ET | 4495 | 0.426099 |
| 11:22 ET | 400 | 0.4244 |
| 11:24 ET | 1520 | 0.4244 |
| 11:26 ET | 200 | 0.4256 |
| 11:27 ET | 300 | 0.4249 |
| 11:29 ET | 200 | 0.42475 |
| 11:31 ET | 800 | 0.425 |
| 11:33 ET | 3400 | 0.4244 |
| 11:38 ET | 300 | 0.4249 |
| 11:40 ET | 356 | 0.4244 |
| 11:42 ET | 200 | 0.4246 |
| 11:44 ET | 232 | 0.4248 |
| 11:45 ET | 400 | 0.4244 |
| 11:47 ET | 200 | 0.4246 |
| 11:49 ET | 100 | 0.4246 |
| 11:51 ET | 200 | 0.4246 |
| 11:54 ET | 600 | 0.4244 |
| 11:56 ET | 25186 | 0.4201 |
| 11:58 ET | 6335 | 0.42 |
| 12:00 ET | 4615 | 0.42 |
| 12:02 ET | 76577 | 0.4113 |
| 12:03 ET | 25656 | 0.4052 |
| 12:05 ET | 6040 | 0.4052 |
| 12:07 ET | 2400 | 0.4114 |
| 12:09 ET | 1338 | 0.413 |
| 12:14 ET | 100 | 0.4131 |
| 12:16 ET | 160 | 0.4148 |
| 12:18 ET | 100 | 0.4131 |
| 12:20 ET | 100 | 0.4131 |
| 12:21 ET | 835 | 0.4114 |
| 12:23 ET | 100 | 0.4129 |
| 12:25 ET | 5224 | 0.4152 |
| 12:27 ET | 1300 | 0.41681 |
| 12:32 ET | 1600 | 0.418 |
| 12:34 ET | 140 | 0.4179 |
| 12:36 ET | 12010 | 0.419 |
| 12:38 ET | 1590 | 0.4189 |
| 12:39 ET | 2329 | 0.4189 |
| 12:41 ET | 1100 | 0.4199 |
| 12:43 ET | 3500 | 0.42 |
| 12:48 ET | 200 | 0.421 |
| 12:50 ET | 918 | 0.4203 |
| 12:52 ET | 1262 | 0.42 |
| 12:54 ET | 962 | 0.4205 |
| 12:56 ET | 140 | 0.42 |
| 12:57 ET | 100 | 0.4208 |
| 12:59 ET | 1649 | 0.42 |
| 01:01 ET | 300 | 0.4207 |
| 01:03 ET | 800 | 0.424 |
| 01:08 ET | 100 | 0.424 |
| 01:10 ET | 5444 | 0.428 |
| 01:15 ET | 475 | 0.428 |
| 01:17 ET | 100 | 0.428 |
| 01:19 ET | 100 | 0.428 |
| 01:21 ET | 120 | 0.428 |
| 01:26 ET | 200 | 0.428 |
| 01:30 ET | 300 | 0.4237 |
| 01:33 ET | 200 | 0.428 |
| 01:37 ET | 200 | 0.4293 |
| 01:42 ET | 200 | 0.4293 |
| 01:46 ET | 300 | 0.4293 |
| 01:50 ET | 100 | 0.4293 |
| 01:51 ET | 2115 | 0.43 |
| 01:53 ET | 4139 | 0.426301 |
| 01:57 ET | 100 | 0.435 |
| 02:00 ET | 300 | 0.4381 |
| 02:02 ET | 800 | 0.435 |
| 02:06 ET | 200 | 0.4381 |
| 02:08 ET | 200 | 0.438 |
| 02:09 ET | 14531 | 0.4383 |
| 02:11 ET | 300 | 0.4381 |
| 02:13 ET | 200 | 0.4407 |
| 02:15 ET | 5139 | 0.43795 |
| 02:18 ET | 9101 | 0.4372 |
| 02:20 ET | 9418 | 0.4399 |
| 02:22 ET | 300 | 0.445 |
| 02:24 ET | 9273 | 0.4434 |
| 02:27 ET | 2000 | 0.443 |
| 02:29 ET | 149 | 0.4424 |
| 02:31 ET | 200 | 0.4467 |
| 02:36 ET | 700 | 0.4467 |
| 02:38 ET | 300 | 0.4457 |
| 02:42 ET | 600 | 0.4426 |
| 02:44 ET | 100 | 0.4448 |
| 02:45 ET | 1044 | 0.4427 |
| 02:47 ET | 200 | 0.4458 |
| 02:49 ET | 800 | 0.4468 |
| 02:51 ET | 100 | 0.447 |
| 02:54 ET | 100 | 0.4489 |
| 02:56 ET | 300 | 0.4489 |
| 02:58 ET | 100 | 0.4489 |
| 03:00 ET | 300 | 0.4458 |
| 03:02 ET | 19435 | 0.4497 |
| 03:07 ET | 7628 | 0.450475 |
| 03:09 ET | 100 | 0.4514 |
| 03:12 ET | 1909 | 0.4518 |
| 03:14 ET | 410 | 0.4524 |
| 03:16 ET | 11240 | 0.454 |
| 03:20 ET | 100 | 0.456 |
| 03:21 ET | 3100 | 0.456 |
| 03:23 ET | 8800 | 0.4588 |
| 03:25 ET | 350 | 0.4574 |
| 03:27 ET | 300 | 0.451901 |
| 03:30 ET | 5053 | 0.466 |
| 03:32 ET | 42820 | 0.4744 |
| 03:34 ET | 58676 | 0.475 |
| 03:36 ET | 1190 | 0.477 |
| 03:38 ET | 83637 | 0.4755 |
| 03:39 ET | 20652 | 0.4742 |
| 03:41 ET | 11392 | 0.4748 |
| 03:43 ET | 400 | 0.4743 |
| 03:45 ET | 3470 | 0.4748 |
Jun 4, 2024
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID, from 8:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
May 22, 2024
BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients, from 8:00AM ET on Wednesday May 22, 2024 by Dow Jones
8:00AM ET on Wednesday May 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioVie Inc | 29.9M | -0.5x | --- |
Raphael Pharmaceutical Inc | 30.6M | -17.7x | --- |
Brainstorm Cell Therapeutics Inc | 30.6M | -1.4x | --- |
Biomx Inc | 29.2M | -0.6x | --- |
NanoViricides Inc | 28.7M | -3.8x | --- |
ProMIS Neurosciences Inc | 31.9M | -2.1x | --- |
Company Information
BioVie Inc. is a clinical-stage company engaged in developing drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions. In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is for the treatment of refractory ascites due to liver cirrhosis. BIV201 is administered as a liquid formulation. The Company is also engaged in developing NE3107, an extracellular single-regulated kinase (ERK) inhibitor that selectively reduces neuroinflammation and insulin resistance. NE3107 is an orally administered small molecule to inhibit inflammation-driven insulin resistance and pathological inflammatory cascades.
Contact Information
- Headquarters
- 680 W NYE LANE, SUITE 201CARSON CITY, NV, United States 89703
- Phone
- 775-888-3162
- Fax
- ---
Executives
- Independent Chairman of the Board
- James Lang
- President, Chief Executive Officer, Director
- Cuong Do
- Chief Financial Officer, Corporate Secretary
- Joanne Kim
- Chief Medical Officer
- Joseph Palumbo
- Independent Director
- Richard Berman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.20 |
EPS | $-0.96 |
Book Value | $0.42 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
